Ginger Capsules for the Prophylactic Treatment of Migraine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

107 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ginger Capsules for the Acute Treatment of Migraine Attacks

NCT02568644

Migraine

COMPLETED NA

Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2

NCT00374530

Headache Migraine

COMPLETED NA

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT01016834

Migraine

COMPLETED PHASE4

A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study

NCT02901756

Migraine

COMPLETED

Effect of Breathing Techniques on Migraine Attacks and Severity

NCT05536635

Migraine Headaches Breathing Techniques

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with the diagnosis of migraine according to the IHS criteria will receive capsules of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three times a day for 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extract of ginger

Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.

Group Type EXPERIMENTAL

Extract of ginger

Intervention Type OTHER

Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.

Cellulose

Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.

Group Type PLACEBO_COMPARATOR

Cellulose

Intervention Type OTHER

Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extract of ginger

Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.

Intervention Type OTHER

Cellulose

Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 and 60 years old;
* Migraine diagnosis;
* Agree to sign the informed consent.

Exclusion Criteria

* Patients with headaches not characterized as migraine;
* Pregnant or lactating women;
* Fertile and sexually active women who do not use contraception;
* Abuse of painkillers, alcohol or other drugs;
* People with hypersensitivity to ginger compounds;
* People with severe neurological diseases (e.g. epilepsy)
* People in use of anticoagulant drugs.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No